儿童原发性免疫性血小板减少症预后因素的研究

doi:10.3760/cma.j.issn.1007-1245.2023.08.019

摘要/Abstract

摘要：

目的　探索影响儿童原发性免疫性血小板减少症（ITP）预后的因素。方法　选择2017年1月至2021年3月在揭阳市人民医院儿科住院的123例ITP患儿进行回顾性研究，收集其临床资料，根据病情分为慢性ITP（CITP）组（20例）与非慢性ITP（NCITP）组（103例）。CITP组男14例，女6例，<3岁7例，≥3岁13例；NCITP组男61例，女42例，<3岁74例，≥3岁29例。分析比较两组患儿的人口学资料、初诊时血小板计数、淋巴细胞绝对值（ALC）、出血评分、初始治疗情况、治疗后血小板峰值及治疗前和治疗后淋巴细胞亚群结果，通过单因素分析影响ITP患儿预后的相关因素。统计学方法采用χ²检验、t检验、非参数U检验。结果　两组初诊时血小板计数比较，差异有统计学意义（Z=-3.45，P<0.05）。治疗后血小板峰值比较，差异有统计学意义（Z=-2.85，P<0.05）。治疗后，CITP组的辅助性T细胞（Th）百分比明显低于NCITP组［（30.52±5.66）%比（35.82±9.08）%］，差异有统计学意义（t=2.51，P<0.05）；初诊时CITP组ALC低于NCITP组［（2.17±1.03）×10⁹/L比（4.68±2.45）×10⁹/L］，差异有统计学意义（t=15.07，P<0.05）。采取对症+免疫球蛋白（IVIG）治疗的ITP患儿中CITP占比8%（8/100），低于单纯采取对症治疗［52.9%（9/17）］和采取对症+IVIG+糖皮质激素治疗［50.0%（3/6）］，差异均有统计学意义（均P<0.05）。治疗后CITP组的Th百分比明显低于NCITP组［（30.52±5.66）%比（35.82±9.08）%］，差异有统计学意义（t=2.51，P<0.05）。结论　年龄≥3岁、初诊时血小板计数偏高及低ALC、治疗后血小板峰值偏低和Th百分比偏低可能是ITP慢性化的危险因素，IVIG治疗对ITP的预后有良好意义。

关键词:

免疫性血小板减少症, 慢性, 儿童, 危险因素

Abstract: Objective　To investigate the prognostic factors of primary immune thrombocytopenia (ITP) in children. Methods　One hundred and twenty-three children with ITP hospitalized in Department of Pediatrics, Jieyang People's Hospital from January 2017 to March 2021 were selected for the retrospective analysis. Their clinical data were collected. According to their conditions, they were divided into a chronic ITP (CITP) group (20 cases) and a non-chronic ITP (NCITP) group (103 cases). There were 14 boys, 6 girls, 7 cases who were <3 years old, and 13 cases who were ≥3 years old in the CITP group. There were 61 boys, 42 girls, 74 cases who were <3 years old, and 29 cases who were ≥3 years old in the NCITP group. The demographic data, platelet counts at first diagnosis, initial absolute lymphocyte counts (ALC), bleeding scores, initial treatment, platelet peak values after treatment, and lymphocyte subsets before and after the treatment were analyzed and compared between the two groups. The related factors affecting their prognosis were analyzed by univariate analysis. χ2 test, t test, and nonparametric U test were applied. Results　There was no statistical difference in the platelet count at first diagnosis between the two groups (Z=-3.45，P<0.05). There was a statistical difference in the platelet count after the treatment between the two groups (Z=-2.85，P<0.05). The percentage of Th cells after the treatment in the CITP group were obviously lower than that in the NCITP group [(30.52±5.66)% vs. (35.82±9.08)%], with a statistical difference (t=2.51，P<0.05). When they were first diagnosed, the ALC in the CITP group was lower than that in the NCITP group [(2.17±1.03)×109/L vs. (4.68±2.45)×109/L], with a statistical difference (t=15.07，P<0.05). Eight percent (8/100) of the children with ITP who took symptomatic treatment and immunoglobulin (IVIG) had CITP, 52.9% (9/17) of the children with ITP who took symptomatic treatment only, and 50.0% (3/6) of the children with ITP who took symptomatic treatment, IVIG, and glucocorticoid, with statistical differences (both P<0.05). After the treatment, the percentage of helper T cells in the CITP group was obviously lower than that in the NCITP group [(30.52 ± 5.66)% vs. (35.82 ± 9.08)%], with a statistical difference (t=2.51, P<0.05). Conclusions　≥ 3 years old, high platelet count and low ALC at first diagnosis, and low platelet peak and low Th cell percentage after treatment may be the risk factors for chronic ITP. IVIG treatment has good significance for the prognosis of children with ITP.

Key words:

Immune thrombocytopenia, Chronic, Children, Risk factors

黄育涛王鸿武.

儿童原发性免疫性血小板减少症预后因素的研究 [J]. 国际医药卫生导报, 2023, 29(8): 1117-1121.

Huang Yutao, Wang Hongwu.

Prognostic factors of primary immune thrombocytopenia in children [J]. International Medicine and Health Guidance News, 2023, 29(8): 1117-1121.

参考文献

[1] 江载芳,申昆玲,沈颖.褚福棠实用儿科学[M].第8版.北京:人民卫生出版社,2015:1896.
[2] Zhang H,Wang L,Quan M,et al.Health-related quality of life in children with chronic immune thrombocytopenia in China[J].Health Qual Life Outcomes,2016,14:45.DOI:10.1186/s12955-016-0445-3.
[3] 谢幸娟,陈振萍.儿童免疫性血小板减少症发病机制研究进展[J].中国实用儿科杂志,2021,36(2):90-94.DOI:10.19538/j.ek2021020603.
[4] 张晴,高长俊.原发免疫性血小板减少症患儿中T淋巴细胞亚群、NK细胞及B细胞在外周血中的表达情况分析[J].实用临床医药杂志,2017,21(17):45-47.DOI:10.7619/jcmp.201717013.
[5] 朱玲玲,张彦,刘开蕾,等.原发性免疫性血小板减少症患者治疗前后T淋巴细胞亚群变化的临床意义[J].中国医药科学,2018,8(17):205-207.DOI:10.3969/j.issn.2095-0616. 2018.17.059.
[6] 中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组,中华医学会儿科学分会血液学组,中华儿科杂志编辑委员会.中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J].中华儿科杂志,2021,59(10):810-819.DOI:10.3760/cma.j.cn112140-20210509-00397.
[7] 国家卫生健康委.儿童原发性免疫性血小板减少症诊疗规范(2019年版)[J].全科医学临床与教育,2019,17(12):1059-1062.DOI:10.13558/j.cnki.issn1672-3686. 2019.012.002.
[8] Semple JW,Italiano JE,Freedman J.Platelets and the immune continuum[J].Nat Rev Immunol,2011,11(4):264-274.DOI:10.1038/nri2956.
[9] 潘艳莎,贾苍松,陈婷婷.不同年龄免疫性血小板减少症患儿临床特点的对比分析[J].中华实用儿科临床杂志,2015,30(3):203-206.DOI:10.3760/j.issn.2095- 428X. 2015.03.011.
[10] Chotsampancharoen T,Sripornsawan P,Duangchoo S,et al.Predictive factors for resolution of childhood immune thrombocytopenia: Experience from a single tertiary center in Thailand[J].Pediatr Blood Cancer,2017,64(1):128-134.DOI:10.1002/pbc.26178.
[11] Güngör T,Arman Bilir Ö,Koşan Çulha V,et al.Retrospective evaluation of children with immune thrombocytopenic purpura and factors contributing to chronicity[J].Pediatr Neonatol,2019,60(4):411-416.DOI:10.1016/j.pedneo. 2018.10.002.
[12] 夏敏.儿童慢性难治性血小板减少症发病机制研究[J].中华实用儿科临床杂志,2015,30(3):164-167.DOI:10.3760/j.issn.2095-428X.2015.03.002.
[13] 旷文勇,郑敏翠,李婉丽,等.原发性免疫性血小板减少症儿童调节性B细胞及淋巴细胞亚群免疫功能失调[J].中国医师杂志,2021,23(9):1321-1325.DOI:10.3760/cma.j.cn431274-20210714-00757.
[14] 李培岭,王欣欣,范蕊,等.T淋巴细胞相关细胞因子与儿童慢性免疫性血小板减少症转归的相关性研究[J].中华实用儿科临床杂志,2020,35(3):206-209.DOI:10.3760/cma.j.cn101070-20190527-00454.
[15] Akbayram S,Karaman K,Dogan M,et al.Initial lymphocyte count as prognostic indicator for childhood immune thrombocytopenia[J].Indian J Hematol Blood Transfus,2017,33(1):93-96.DOI:10.1007/s12288-016-0664-0.
[16] 王峰,娜斯曼·尼加提,黎瞳,等.影响儿童原发性免疫性血小板减少症临床预后因素的研究[J].中国小儿血液与肿瘤杂志,2021,26(2):93-97.DOI:10.3969/j.issn.1673-5323. 2021.02.007.
[17] Heitink-Pollé KM,Nijsten J,Boonacker CW,et al.Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis[J].Blood,2014,124(22):3295-3307.DOI:10.1182/blood-2014-04-570127.
[18] Bennett CM,Neunert C,Grace RF,et al.Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the intercontinental cooperative ITP study group registry II participants[J].Pediatr Blood Cancer,2018,65(1).DOI:10.1002/pbc.26736.
[19] 孙晓雅,盛光耀.不同一线治疗对儿童免疫性血小板减少症病程的影响[J].河南医学研究,2019,28(10):1789-1791.DOI:10.3969/j.issn.1004-437X.2019.10.020.
[20] 洪志明,薛嘉泓,吴静,等.IVIG冲击疗法对免疫性血小板减少症患儿T淋巴细胞的影响及治疗效果[J].吉林医学,2022,43(7):1784-1786.DOI:10.3969/j.issn.1004-0412. 2022.07.015.